10-Baggas Factory 10

[budfoxfun]

$ENTB Mr. Koos noted the following key milestones achieved by Zander Therapeutics:

1. Expansion of the management team.

2. Appointment of strong scientific advisors to help guide the company forward

3. Filing of patent applications for small molecule therapies in animals

4. Medicinal chemistry refinement and expansion of compounds modulating checkpoint NR2F6 (through licensor)

5. Initiation of ex vivo studies on modulating NR2F6 in canines through ChemDiv, Inc. (a well-respected contract research organization) SAN DIEGO, April 26, 2017 /PRNewswire/ --Entest BioMedical Inc.'s (ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary, Zander Therapeutics Inc. Specifically, Zander Therapeutics is moving forward in the area of immunotherapy delivered through small molecule treatments. The company is the exclusive licensee for veterinary applications of Regen BioPharma's intellectual property for modulating the checkpoint NR2F6 to treat cancer and arthritis.Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs
https://finance.yahoo.com/news/entest-biomedicals-chairman-discusses-subsidiary-123000276.html